Trevena Investor Relations Material

Trevena Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines targeted at central nervous system (CNS) disorders. The company's portfolio includes OLINVYK (oliceridine) injection, which is approved for use in adults to manage acute pain severe enough to require an intravenous opioid analgesic when alternative treatments are inadequate. Trevena also has several investigational drug candidates in its pipeline. The company is headquartered in Chesterbrook, Pennsylvania, and its shares are listed on the NASDAQ.